877624-37-8

Basic information

• Product Name: Benzoic acid, 4-bromo-3-(dibromomethyl)-, methyl ester
• CAS NO: 877624-37-8
• Molecular Formula: C9H7Br3O2
• Molecular Weight: 386.865
• Mol File: 877624-37-8.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 4-bromo-3-(dibromomethyl)-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 4-bromo-3-(dibromomethyl)-, methyl ester(877624-37-8)
• EPA Substance Registry System: Benzoic acid, 4-bromo-3-(dibromomethyl)-, methyl ester(877624-37-8)

Safety Data

• Hazardous Substances Data: 877624-37-8(Hazardous Substances Data)

Upstream product

• 99548-55-7 4-bromo-2-methyl-benzoic acid methyl ester 
• 148547-19-7 4-Bromo-3-methylbenzoic acid methyl ester 

Downstream Products

• 1256242-36-0 methyl 6-bromo-3-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)benzoate 
• 254746-40-2 methyl 4-bromo-3-(hydroxymethyl)benzoate 
• 902137-33-1 3-(Benzyloxyimino-methyl)-4-[(S)-2-((E)-2-ethoxycarbonyl-vinyl)-5-oxo-pyrrolidin-1-yl]-benzoic acid methyl ester 
• 902137-42-2 (S)-1-[2-(Benzyloxyimino-methyl)-4-methoxycarbonyl-phenyl]-5-oxo-pyrrolidine-2-carboxylic acid ethyl ester 
• 902137-32-0 methyl 4-bromo-3-[(phenylmethoxyimino)methyl]benzoate 
• 858124-35-3 4-bromo-3-formyl-benzoic acid methyl ester 

Relevant articles and documents

GPR40 AGONISTS

This disclosure is directed, at least in part, to GPR40 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR40 agonists are gut-restricted compounds. In some embodiments, the GPR40 agonists are full agonists or partial agonists. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.

Total synthesis of (-)-martinellic acid via radical addition-cyclization- elimination reaction

(Chemical Equation Presented) The asymmetric total synthesis of martinellic acid, the first pyrrolo[3,2-c]quinoline alkaloid found in nature, is described. Three key steps in our synthesis of (-)-martinellic acid are the Bu 3SnH-promoted radica

2-SULFANYL-BENZOIMIDAZOL-1-YL-ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS

The invention relates to 2-sulfanyl-benzoimidazol-1-yl-acetic acid derivatives and their use as potent "chemoattractant receptor-homologous molecule expressed on Th2 cells" antagonists in the treatment of prostaglandin mediated diseases, to pharmaceutical compositions containing these derivatives and to processes for their preparation.